Skip to main content
. 2022 Jan 10;24:443–451. doi: 10.1016/j.omto.2022.01.002

Figure 3.

Figure 3

T cells expressing humanized CAR-targeting IL-13Rα2 exhibit impressive anti-GBM efficacy in a subcutaneous xenograft mouse model

(A) Schematic diagram of the generation of GBM xenograft mouse model and the ministration of CAR-T cells. (B) A xenograft mouse model was generated via U251-eGFP-Luc cells subcutaneous injection and followed by the treatment of T cells. The tumor growth was monitored by using the IVIS system. (C) The luciferase signal was quantified by using Living Image® 3.2 software. (D) The overall survival was measured using Kaplan-Meier method, with Cox proportional hazard regression analysis for group comparison. Statistical significance was set at p<0.05.